EW
$90.82+0.29%
as of close, Oct 27, 2026
☾ AH $90.82 +0.29%
Edwards Lifesciences CorporationStock · HealthcareS&P 500 Equal Weight · 0.2% of RSPS&P 500 · 0.08% of SPYRussell 1000 · 0.07% of IWBUS Stock Market · 0.07% of VTIRussell 3000 · 0.07% of IWVMSCI World · 0.06% of URTHMSCI ACWI · 0.05% of ACWI
EW — Edwards Lifesciences Corporation price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeSEEEEEEEEEEEEEEEEEEEEE
30.040.050.060.070.080.090.0100.0110.0120.0130.0050.0M$90.82—20162019202120242026
2026-10-27
Price$90.82
MA20$87.79
MA50$84.13
Vol12.5M
Key stats#
Price data
- Price
- $90.82
- YTD price return
- +6.53%
- YTD total return
- +6.53%
- Next earnings
- Nov 4, 2026 · After close
- Market cap
- 52.3B
- Enterprise value
- 48.9B
- Shares outstanding
- 576.4M
- 52W low
- $74.66
- 52W high
- $96.29
- From 52W high
- -5.68%
- From 52W low
- +21.64%
- 52W range
- 75%
- Beta
- 0.84
Volume
- Rel volume
- 0.84×
- 30D volume
- 3.6M
- 30D $ vol
- 314.6M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- −$53K
- Insider net 3M
- −$3.5M
- Insider net 1Y
- −$21.3M
Form 4 transactions by trade date, as filed; latest on file 2026-10-08.
Fundamentals
- Sales (ttm)
- 6.5B
- Sales/share
- $11.30
- EPS (ttm)
- $1.73
- FCF (ttm)
- 1.4B
- FCF/share
- $2.49
- Book value/share
- $18.42
- Net margin
- 15.43%
- ROE
- 9.46%
- ROA
- 7.25%
- Debt / equity
- 0.06×
- Current ratio
- 4.52
Growth (CAGR, ttm) · 10Y
- Sales
- +14.56%+15.29%+5.75%+9.03%
- Net income
- -75.80%-10.24%-7.23%+6.64%
- FCF
- +144.00%+26.85%+6.41%+11.67%
- Shares
- -1.82%-1.76%-1.55%-1.02%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- -75.15%-8.52%-5.80%+7.92%
- Sales/share
- +16.69%+17.36%+7.41%+10.16%
- FCF/share
- +148.53%+29.12%+8.09%+12.82%
- Book value/share
- +2.56%+20.65%+17.47%+16.89%
- Price
- +12.38%+13.74%-4.79%+11.20%
- Total return
- +12.38%+13.74%-4.79%+11.20%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 52.5×
- P/OI (ttm)
- 36.1×
- Fwd P/E
- 26.4×
- P/S (ttm)
- 8.0×
- P/B (mrq)
- 4.9×
- P/FCF (ttm)
- 36.5×
- EV/EBITDA (fy)
- 30.3×
- EV/Sales (ttm)
- 7.5×
- FCF yield (ttm)
- 2.74%
- Buyback yield (realized, 1y)
- 1.82%
- Shareholder yield (realized, 1y)
- 1.82%
- Buyback yield (cash, ttm)
- 2.30%
- Shareholder yield (cash, ttm)
- 2.30%
Vs own 10Y history
- P/E
- 82nd
- P/OI
- 50th
- P/S
- 29th
- P/B
- 20th
- P/FCF
- 12th
Bar = where today’s multiple sits in EW’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-27#
1D
+0.29%
5D
+2.87%
1M
+5.25%
3M
+9.37%
YTD
+6.53%
1Y
+12.37%
5Y
-21.75%
Recent filings#
- Aug 31Insider sale · Dahl Andrew M. (SVP, Corporate Controller) sold 544 shares for $50K at $91.06
- Aug 28Insider sale · Bruls Annette (CVP, EMEACLA) sold 2,644 shares for $238K at $89.98
- Aug 26Insider sale · Chopra Daveen (CVP, TMTT, Surgical & IHFM) sold 31,800 shares for $2.9M at $90.99–$91.76
- Aug 26Insider sale · Markowitz Wayne (CVP, JAPAC) sold 11,014.313 shares for $945K on 3 days since Jul 28
- Jul 27Insider sale · Zovighian Bernard J (CEO · Director) sold 2,920.551 shares for $245K at $83.93
Financial statements
Open full EW financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +8.32% | +0.22% |
| JNJ | Johnson & Johnson | -0.92% | +0.91% |
| ABBV | AbbVie Inc. | +8.34% | -0.12% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +8.98% | -0.08% |
| MRK | Merck & Co. Inc. | -4.68% | +0.86% |
| NVS | Novartis AG | +7.84% | +1.98% |
| TMO | Thermo Fisher Scientific Inc. | +2.67% | +1.19% |
| AMGN | Amgen Inc. | +8.04% | +0.75% |
